Astrazeneca PLC (NYSE:AZN) Downgraded by BidaskClub

Astrazeneca PLC (NYSE:AZN) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, July 24th.

AZN has been the topic of several other reports. HSBC Holdings plc downgraded Astrazeneca PLC from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Credit Suisse Group raised Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a report on Friday, May 12th. Jefferies Group LLC reissued a “hold” rating on shares of Astrazeneca PLC in a report on Monday, April 10th. Finally, UBS AG cut shares of Astrazeneca PLC from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $35.44 to $25.55 in a research report on Wednesday, April 5th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $33.39.

Astrazeneca PLC (NYSE AZN) traded up 0.14% during mid-day trading on Monday, reaching $29.12. The company had a trading volume of 4,185,092 shares. The stock has a market capitalization of $73.73 billion, a price-to-earnings ratio of 19.10 and a beta of 0.74. The company’s 50 day moving average is $31.67 and its 200 day moving average is $31.48. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60.

Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. Astrazeneca PLC’s revenue was down 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.83 EPS. Equities analysts predict that Astrazeneca PLC will post $1.86 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (NYSE:AZN) Downgraded by BidaskClub” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.com-unik.info/2017/08/19/astrazeneca-plc-nyseazn-cut-to-sell-at-bidaskclub-updated-updated-updated.html.

Hedge funds have recently added to or reduced their stakes in the stock. Atria Investments LLC boosted its stake in Astrazeneca PLC by 11.4% in the first quarter. Atria Investments LLC now owns 24,566 shares of the company’s stock worth $765,000 after buying an additional 2,521 shares in the last quarter. Capstone Asset Management Co. boosted its stake in Astrazeneca PLC by 6.9% in the first quarter. Capstone Asset Management Co. now owns 103,471 shares of the company’s stock worth $3,222,000 after buying an additional 6,660 shares in the last quarter. LVM Capital Management Ltd. MI boosted its stake in Astrazeneca PLC by 11.4% in the first quarter. LVM Capital Management Ltd. MI now owns 9,800 shares of the company’s stock worth $305,000 after buying an additional 1,000 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock worth $138,000 after buying an additional 2,805 shares in the last quarter. Finally, Creative Planning boosted its stake in Astrazeneca PLC by 9.8% in the first quarter. Creative Planning now owns 45,321 shares of the company’s stock worth $1,411,000 after buying an additional 4,040 shares in the last quarter. Institutional investors and hedge funds own 14.30% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit